Skip to main content
SpringerLink
Log in

Combination Antiretroviral Therapy in HIV Infection

An Economic Perspective

  • Current Opinion
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–191

    Article  PubMed  CAS  Google Scholar 

  2. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–587

    Article  PubMed  CAS  Google Scholar 

  3. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-2 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762–768

    PubMed  CAS  Google Scholar 

  4. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: ACTG 089. J Infect Dis 1995; 171 Suppl. 2: S123–S130

    Article  PubMed  Google Scholar 

  5. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus. N Engl J Med 1990; 322: 941–949

    Article  PubMed  CAS  Google Scholar 

  6. Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine therapy in HIV infection. Arch Intern Med 1996; 156: 1073–1077

    Article  PubMed  CAS  Google Scholar 

  7. D’Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408

    PubMed  Google Scholar 

  8. Hammer S, Katzenstein M, Hughes H, et al. Nucleoside monotherapy versus combination therapy in HIV-infected adults: a randomized, double-blind placebo-controlled trial in persons with CD4 cell counts 200–500/mm3 [abstract no. LB-1]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20: San Francisco (CA). Washington DC: American Society for Microbiology, 1995

    Google Scholar 

  9. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662–1669

    Article  PubMed  CAS  Google Scholar 

  10. Ridhy T, Leis J. Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 1995; 270: 29621–29623

    Article  Google Scholar 

  11. Collier CA, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus disease. N Engl J Med 1996; 334: 1011–1017

    Article  PubMed  CAS  Google Scholar 

  12. Gulick R, Mellors J, Havlir D, et al. Potent and sustained anti-retroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) [abstract no. LB7]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington DC. Alexandria (VA): Infectious Disease Society of America, 1996

    Google Scholar 

  13. Massari F, Conant M, Mellors J, et al. A phase II open-label randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract no. 200]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington DC. Alexandria (VA): Infectious Disease Society of America, 1996

    Google Scholar 

  14. New drugs for HIV infection. Medical Letter 1996; 38: 35-8

    Google Scholar 

  15. Fortgang IS, Moore RD. Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland. J Acquir Immune Defic Syndr 1995; 8: 365–372

    CAS  Google Scholar 

  16. Moore RD. Hidalgo J, Bareta JC, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994; 7: 349–354

    PubMed  CAS  Google Scholar 

  17. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–478

    Article  PubMed  CAS  Google Scholar 

  18. Chaisson RE. Keruly JC. Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751–756

    Article  PubMed  CAS  Google Scholar 

  19. O’Brien WA. Hartigan PM. Martin D. et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426–431

    Article  PubMed  Google Scholar 

  20. Paul SD, Kuntz KM. Eagle KA. et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–1149

    Article  PubMed  CAS  Google Scholar 

  21. Hamilton VH. Racicot FE. Zowall H. et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995; 273: 1032–1038

    Article  PubMed  CAS  Google Scholar 

  22. Lindfors KK. Rosenquist J. The cost-effectiveness of mammographic screening strategies. JAMA 1995; 274: 881–884

    Article  PubMed  CAS  Google Scholar 

  23. Van Dam J, Bond JH. Sivak MV. Fecal occult blood screening for colorectal cancer. Arch Int Med 1995; 155: 2389–2402

    Article  Google Scholar 

  24. Hornberger JC. The hemodialysis prescription and cost-effectiveness. J Am Soc Nephrol 1993: 4: 1021–1027

    PubMed  CAS  Google Scholar 

  25. Gage BF. Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839–1845

    Article  PubMed  CAS  Google Scholar 

  26. Krahn MD, Mahoney JE. Eckman MH. et al. Screening for prostate cancer. JAMA 1994; 272: 773–780

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, 1830 E. Monument Street, Room 8059, Baltimore, Maryland, 21205, USA

    Richard D. Moore & John G. Bartlett

Authors
  1. Richard D. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John G. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, R.D., Bartlett, J.G. Combination Antiretroviral Therapy in HIV Infection. Pharmacoeconomics 10, 109–113 (1996). https://doi.org/10.2165/00019053-199610020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610020-00002

Keywords

Search

Navigation